Metoprolol Succinate (ER) 50 Mg + Ramipril 5 Mg Tablets – AMIPRIL M 5/50

Metoprolol Succinate (ER) 50 Mg + Ramipril 5 Mg Tablets – Synergistic Cardioprotection with Dual Mechanism Control.

Amipril M 5/50 – Ramipril 5mg + Metoprolol 50mg extended-release tablet offers a combined dual mechanism of support for cardiovascular management. Ramipril, an ACE inhibitor, reduces vascular resistance and blood pressure by blocking the conversion of angiotensin I to angiotensin II. While Metoprolo, a selective beta-1 blocker, decreases heart rate and myocardial oxygen demand. The combination is especially beneficial in hypertension, heart failure, and post-MI care.

Recommended by specialists:
✅Cardiologists – For managing hypertension, heart failure, and post-myocardial infarction (heart attack) patients.
✅General Physicians– For routine high blood pressure and cardiovascular risk management.

Key benefits of Metoprolol Succinate (ER) 50 Mg + Ramipril 5 Mg Tablets – AMIPRIL M 5/50:
✅Combined action – Ramipril works by RAAS Inhibition mechanism while Metoprolol reduces sympathetic drive, providing comprehensive blood pressure and cardiac workload control.
✅Cardiovascular Risk Reduction – Ideal for hypertensive and post-myocardial infarction patients as it improves cardiac output and prevents remodelling.
✅Sustained Release Formulation – Metoprolol in sustained release form ensures stable blood plasma levels, supporting better patient compliance and maintaining round-the-clock protection.

Indications:
✅Hypertension
✅Chronic Heart Failure
✅Post-Myocardial Infarction
✅Ischemic Heart Disease
✅Left Ventricular Dysfunction